Alivus Life Sciences LimitedQ1 FY27 Results & Financial Update
Alivus Life Sciences Limited: Q1 FY27 standalone results and company financials – revenue ₹640.41 Cr, PAT ₹160.08 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Alivus Life Sciences price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Alivus Life Sciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Alivus Life Sciences reported revenue from operations of INR 640.414 crore for the quarter ended June 30, 2026, supported by robust momentum in its non-GPL business which grew 26.5% year-on-year.
Total income for Q1 FY27 reached INR 662.815 crore, inclusive of other income amounting to INR 22.401 crore.
Net profit after tax (PAT) for the quarter stood at INR 160.076 crore, while profit before tax (PBT) was reported at INR 212.223 crore.
s in results press releases, EBITDA expanded by 29.1% year-on-year to INR 234.10 crore, driven by a favourable product mix, successful new product launches, and operating leverage, lifting EBITDA margin to 36.6%.
The GPL (Glenmark Pharmaceuticals Ltd.) business experienced a 52.6% year-on-year decline during the quarter due to inventory rationalization, though management expects this segment to recover in the second half of the financial year.
The company generated a strong free cash flow of INR 90.10 crore during Q1 FY27, bolstering its cash and cash equivalents (including short-term investments) to INR 880.20 crore as of June 30, 2026, while maintaining a net debt-free balance sheet.
Profit after tax was ₹160.08 Cr for the reported quarter. EPS was ₹13.01 for the reported quarter.
01 · Business model
What does Alivus Life Sciences do?
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) is a developer and manufacturer of select, high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) focusing on chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management, and diabetes.
The company also provides Contract Development and Manufacturing Organization (CDMO) services to multinational and specialty pharmaceutical companies across global markets.
Operating through four manufacturing facilities located in Ankleshwar, Dahej, Mohol, and Kurkumbh with an aggregate annual installed reactor capacity of 1,424 KL, the company maintains regulatory compliance inspected by global authorities including the USFDA, PMDA, and EDQM.
Alivus distributes its diversified portfolio of 181 molecules across customers in India, Europe, North America, Latin America, Japan, and the Rest of the World.
02 · Historical context
What shaped the business before this quarter
Previously operating as Glenmark Life Sciences Limited, the company transitioned its corporate identity to Alivus Life Sciences Limited to reflect its evolving independent market positioning.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹640.41 Cr |
| Total income | ₹662.82 Cr |
| Profit before tax | ₹212.22 Cr |
| Profit after tax | ₹160.08 Cr |
| EPS | ₹13.01 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 25.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 33.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹22.40 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Non-GPL revenue grew by 26.5% year-on-year to INR 568.10 crore, accounting for 88.7% of total revenues and offsetting a temporary decline in the GPL channel.
Regulated markets contributed 83% of Q1 FY27 revenues, sustained by stable product demand across major international geographies.
What drove margins
Gross margins reached 60.2% (up 510 bps year-on-year) and EBITDA margins reached 36.6%, supported by a favorable product mix, new product rollouts, and operating leverage.
05 · Demand, customers & order book
Where demand is coming from
Cumulative DMF and CEP filings reached 617 across major international markets as of June 30, 2026.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Generic API revenues rose 7.4% year-on-year to INR 592.10 crore (94% of segment mix), while CDMO revenues grew 3.8% year-on-year to INR 37.80 crore.
GPL business revenue contracted to INR 72.30 crore (11.3% of total revenue) due to inventory rationalization, though management expects a recovery in H2 FY27.
Geography and market mix
Regulated markets accounted for 83% of quarterly revenue, with emerging markets and India contributing the remaining 17%.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
Construction work for Phase 1 (350 KL capacity) and Phase 2 (115 KL capacity) at the Solapur greenfield facility is underway, with completion scheduled for Q3 FY27 and Q4 FY27 respectively.
Construction has commenced on a new state-of-the-art R&D facility in Taloja (Navi Mumbai) focusing on flow chemistry, complex products, particle engineering, and green chemistry.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The high-potency API portfolio includes 29 active grid products (13 validated, 7 in advanced development, 9 in lab development). The iron complexes portfolio advanced with filing completed for one compound and others in development.
09 · Reported developments
What changed operationally
Achieved highest-ever EBITDA margin of 36.6% and a 31.8% year-on-year increase in reported PAT in the press release metrics.
10 · Pressure points & risks
What is not going smoothly
GPL business witnessed a 52.6% year-on-year de-growth during Q1 FY27 due to client-side inventory rationalization.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
The company generated a free cash flow of INR 90.10 crore during Q1 FY27.
Capital allocation & funding
Alivus remained net debt-free with cash, cash equivalents, and short-term investments totaling INR 880.20 crore as of June 30, 2026.
12 · Management guidance & targets
What management is targeting from here
Management expects full-year revenue growth of 10% to 12% and EBITDA margins to sustain in the 30% to 32% range, while anticipating the GPL business to be flattish for the full fiscal year.
13 · Beyond the numbers
What changed beyond the numbers
Reported update
Corporate Identity Transition
The company officially operated under its new name, Alivus Life Sciences Limited, following its transition from Glenmark Life Sciences Limited.
14 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations adjusted from INR 689.117 crore in Q4 FY26 to INR 640.414 crore in Q1 FY27.
15 · Key Q&A
The quarter, answered directly
What does Alivus Life Sciences do?
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) is a developer and manufacturer of select, high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) focusing on chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management, and diabetes.
What is the clearest takeaway from Q1 FY27?
Alivus Life Sciences reported revenue from operations of INR 640.414 crore for the quarter ended June 30, 2026, supported by robust momentum in its non-GPL business which grew 26.5% year-on-year.
What drove revenue or demand?
Non-GPL revenue grew by 26.5% year-on-year to INR 568.10 crore, accounting for 88.7% of total revenues and offsetting a temporary decline in the GPL channel.
What mattered most for margins or profitability?
Gross margins reached 60.2% (up 510 bps year-on-year) and EBITDA margins reached 36.6%, supported by a favorable product mix, new product rollouts, and operating leverage.
What changed operationally beyond the headline numbers?
Construction work for Phase 1 (350 KL capacity) and Phase 2 (115 KL capacity) at the Solapur greenfield facility is underway, with completion scheduled for Q3 FY27 and Q4 FY27 respectively.
What is management guiding or targeting from here?
Management expects full-year revenue growth of 10% to 12% and EBITDA margins to sustain in the 30% to 32% range, while anticipating the GPL business to be flattish for the full fiscal year.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Solapur Project Commissioning: Monitor the scheduled commissioning of Solapur Phase 1 (350 KL) in Q3 FY27 and Phase 2 (115 KL) in Q4 FY27.
- 02
GPL Segment Recovery: Track the anticipated recovery of the GPL business segment during the second half of FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.